Meeting
2022 ASCO Annual Meeting
Outcomes of single-agent PD-(L)-1 versus combination with chemotherapy in patients with PD-L1-high (≥ 50%) lung cancer.
Authors
Arielle Elkrief
Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
Arielle Elkrief , Joao Victor Machado Alessi , Biagio Ricciuti , Hira Rizvi , Isabel Ruth Preeshagul , Jacklynn V. Egger , Jamie E. Chaft , Charles M. Rudin , Gregory J. Riely , Mark G. Kris , Marc Ladanyi , Matthew D. Hellmann , Mark M. Awad , Adam Jacob Schoenfeld
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9052)
DOI
10.1200/JCO.2022.40.16_suppl.9052
Abstract #
9052
Poster Bd #
40
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status.
First Author: Charu Aggarwal
Poster
2022 ASCO Annual Meeting
Molecular characterization of NF1-mutated NSCLC and clinical outcomes.
First Author: Christopher Gates
Poster
2023 ASCO Annual Meeting
Co-mutational status and PD-L1 expression in KRAS mutant non-small cell lung cancer (NSCLC): Role in treatment selection and association with clinical outcomes.
First Author: Hina Khan
Poster
2019 ASCO Annual Meeting
Molecular correlates of PD-L1 expression in patients with non-small cell lung cancer.
First Author: Hira Rizvi